Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.
2018
3578Background: Matrix metalloproteinase 9 is highly expressed in several malignancies, including metastatic colorectal cancer (mCRC) and is an adverse prognostic feature. In preclinical colorectal...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI